Sorrento Therapeutics (SRNE) 11.41 $SRNE
Sorrento to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Thu Feb 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at an upcoming healthcare conference.
SRNE: 11.41 (+0.56)
Sorrento Announces Retention of Glen Sato to Provide Strategic Support
PR Newswire - Mon Feb 02, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that Glen Sato, former Chief Financial Officer at PDL Biopharma, Inc. and Exelixis, Inc., and partner at Cooley LLC, has been retained to provide support for the ongoing strategic financial and legal initiatives in the business and operations of the Company.
SRNE: 11.41 (+0.56)
Sorrento Announces Completion of Enrollment in the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire Europe - Wed Jan 28, 8:02AM CST
Sorrento Therapeutics, Inc. , an oncology company developing new treatments for cancer and associated pain, announced today that the last patient in (total n = 111 patients) has been randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial. Patients were enrolled globally from sites in USA, Eastern Europe, and Asia. The ongoing safety assessment from treated patients continues to reveal no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel. Previously, Sorrento announced positive pharmacokinetic (PK) data from the first eight (
patients enrolled in the TRIBECA study.
SRNE: 11.41 (+0.56)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 11:45AM CST
DRD: 2.27 (+0.10), OCN: 9.10 (+0.09), BBRY: 10.09 (+0.23), DCIX: 2.20 (+0.02), BBY: 39.11 (-0.08), RIC: 3.29 (-0.09), FISH: 22.86 (-0.24), NVGN: 2.79 (+0.17), SRNE: 11.41 (+0.56), WNS: 23.12 (+0.36), LPSN: 10.74 (+0.38), MUX: 1.10 (+0.06), ATNM: 3.60 (-0.29), PODD: 32.00 (-0.07), EDUC: 4.18 (-0.13), NGD: 3.73 (-0.04), PPC: 26.75 (+0.77), MOV: 25.26 (-0.17), KONE: 4.20 (+0.03), EHTH: 10.91 (-0.04)
Today's Weak On High Volume Stock: Sorrento Therapeutics (SRNE)
at The Street - Thu Jan 15, 9:02AM CST
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a weak on high relative volume candidate
SRNE: 11.41 (+0.56)
Sorrento Provides Status Update on the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire - Mon Jan 12, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January. Patients were recruited globally from over 20 sites in USA, Eastern Europe, and Asia. The initial safety assessment from treated patients revealed no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel.
SRNE: 11.41 (+0.56)
Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong
PR Newswire - Tue Jan 06, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, announced today that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, is scheduled to present details about Conkwest's Neukoplast technology platform and the exclusive partnership among Sorrento, Conkwest and NantWorks to develop and commercialize "CAR.TNK" (Chimeric Antigen Receptor Tumor-attacking Neukoplast) Cell Lines, the next-generation "off-the-shelf" adoptive cancer immunotherapy.
SRNE: 11.41 (+0.56)
Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco
PR Newswire - Mon Jan 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at two upcoming healthcare conferences.
SRNE: 11.41 (+0.56)
Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
Business Wire - Mon Dec 29, 1:40PM CST
Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast(TM) (NK-92(TM)), a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D. to the Company's Board of Directors. Mr. Rosen is President of Heron Therapeutics (NASDAQ:HRTX) and Dr. Ji is co-founder, President and CEO of Sorrento Therapeutics, Inc. (NASDAQ:SRNE).
HRTX: 10.29 (+0.39), LJPC: 18.79 (unch), SRNE: 11.41 (+0.56)
Strong On High Volume: Sorrento Therapeutics (SRNE)
at The Street - Mon Dec 29, 9:02AM CST
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a strong on high relative volume candidate
SRNE: 11.41 (+0.56)
Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board
PR Newswire - Wed Dec 24, 7:00AM CST
Conkwest, Inc., the Natural Killer Cell Company of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast® (NK-92(TM)) as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, has entered into a definitive agreement to purchase approximately $48 million of the Company's Class A Common Stock. In connection with the investment, he will be named Co-Chairman of the Conkwest Board of Directors. An additional $2 million of Class A Common Stock is being purchased separately by Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
SRNE: 11.41 (+0.56)
Sorrento Announces Two Strategic Partnerships To Boost Funding And Validate Its Technology
Tony Schwartz, PhD - at Seeking Alpha - Mon Dec 22, 9:50AM CST
SRNE: 11.41 (+0.56)
Sorrento Therapeutics, Inc. - Product Pipeline Review - 2014
PR Newswire - Mon Dec 22, 7:41AM CST
Sorrento Therapeutics, Inc. - Product Pipeline Review - 2014
SRNE: 11.41 (+0.56)
Sorrento and Conkwest Announce Exclusive Global Collaboration
PR Newswire Europe - Fri Dec 19, 5:01AM CST
-- Developing Next Generation Cancer Immunotherapy with "Off-the-Shelf" Chimeric Antigen Receptor-Tumor Attacking Natural Killer (CAR-TNK(TM)) Cell Lines
SRNE: 11.41 (+0.56)
Perception, Opportunity in Volatility: Analyst Notes on Oracle, Riverbed, ExxonMobil, Sorrento Therapeutics and AES
PR Newswire - Tue Dec 16, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
SRNE: 11.41 (+0.56)
Sorrento up on news of collaboration with Abraxane inventor
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 12:40PM CST
SRNE: 11.41 (+0.56)
Sorrento to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Thu Feb 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at an upcoming healthcare conference.
SRNE: 11.41 (+0.56)
Sorrento Announces Retention of Glen Sato to Provide Strategic Support
PR Newswire - Mon Feb 02, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that Glen Sato, former Chief Financial Officer at PDL Biopharma, Inc. and Exelixis, Inc., and partner at Cooley LLC, has been retained to provide support for the ongoing strategic financial and legal initiatives in the business and operations of the Company.
SRNE: 11.41 (+0.56)
Sorrento Announces Completion of Enrollment in the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire Europe - Wed Jan 28, 8:02AM CST
Sorrento Therapeutics, Inc. , an oncology company developing new treatments for cancer and associated pain, announced today that the last patient in (total n = 111 patients) has been randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial. Patients were enrolled globally from sites in USA, Eastern Europe, and Asia. The ongoing safety assessment from treated patients continues to reveal no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel. Previously, Sorrento announced positive pharmacokinetic (PK) data from the first eight (
patients enrolled in the TRIBECA study. SRNE: 11.41 (+0.56)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 11:45AM CST
DRD: 2.27 (+0.10), OCN: 9.10 (+0.09), BBRY: 10.09 (+0.23), DCIX: 2.20 (+0.02), BBY: 39.11 (-0.08), RIC: 3.29 (-0.09), FISH: 22.86 (-0.24), NVGN: 2.79 (+0.17), SRNE: 11.41 (+0.56), WNS: 23.12 (+0.36), LPSN: 10.74 (+0.38), MUX: 1.10 (+0.06), ATNM: 3.60 (-0.29), PODD: 32.00 (-0.07), EDUC: 4.18 (-0.13), NGD: 3.73 (-0.04), PPC: 26.75 (+0.77), MOV: 25.26 (-0.17), KONE: 4.20 (+0.03), EHTH: 10.91 (-0.04)
Today's Weak On High Volume Stock: Sorrento Therapeutics (SRNE)
at The Street - Thu Jan 15, 9:02AM CST
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a weak on high relative volume candidate
SRNE: 11.41 (+0.56)
Sorrento Provides Status Update on the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire - Mon Jan 12, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January. Patients were recruited globally from over 20 sites in USA, Eastern Europe, and Asia. The initial safety assessment from treated patients revealed no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel.
SRNE: 11.41 (+0.56)
Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong
PR Newswire - Tue Jan 06, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, announced today that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, is scheduled to present details about Conkwest's Neukoplast technology platform and the exclusive partnership among Sorrento, Conkwest and NantWorks to develop and commercialize "CAR.TNK" (Chimeric Antigen Receptor Tumor-attacking Neukoplast) Cell Lines, the next-generation "off-the-shelf" adoptive cancer immunotherapy.
SRNE: 11.41 (+0.56)
Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco
PR Newswire - Mon Jan 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at two upcoming healthcare conferences.
SRNE: 11.41 (+0.56)
Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
Business Wire - Mon Dec 29, 1:40PM CST
Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast(TM) (NK-92(TM)), a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D. to the Company's Board of Directors. Mr. Rosen is President of Heron Therapeutics (NASDAQ:HRTX) and Dr. Ji is co-founder, President and CEO of Sorrento Therapeutics, Inc. (NASDAQ:SRNE).
HRTX: 10.29 (+0.39), LJPC: 18.79 (unch), SRNE: 11.41 (+0.56)
Strong On High Volume: Sorrento Therapeutics (SRNE)
at The Street - Mon Dec 29, 9:02AM CST
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a strong on high relative volume candidate
SRNE: 11.41 (+0.56)
Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board
PR Newswire - Wed Dec 24, 7:00AM CST
Conkwest, Inc., the Natural Killer Cell Company of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast® (NK-92(TM)) as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, has entered into a definitive agreement to purchase approximately $48 million of the Company's Class A Common Stock. In connection with the investment, he will be named Co-Chairman of the Conkwest Board of Directors. An additional $2 million of Class A Common Stock is being purchased separately by Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
SRNE: 11.41 (+0.56)
Sorrento Announces Two Strategic Partnerships To Boost Funding And Validate Its Technology
Tony Schwartz, PhD - at Seeking Alpha - Mon Dec 22, 9:50AM CST
SRNE: 11.41 (+0.56)
Sorrento Therapeutics, Inc. - Product Pipeline Review - 2014
PR Newswire - Mon Dec 22, 7:41AM CST
Sorrento Therapeutics, Inc. - Product Pipeline Review - 2014
SRNE: 11.41 (+0.56)
Sorrento and Conkwest Announce Exclusive Global Collaboration
PR Newswire Europe - Fri Dec 19, 5:01AM CST
-- Developing Next Generation Cancer Immunotherapy with "Off-the-Shelf" Chimeric Antigen Receptor-Tumor Attacking Natural Killer (CAR-TNK(TM)) Cell Lines
SRNE: 11.41 (+0.56)
Perception, Opportunity in Volatility: Analyst Notes on Oracle, Riverbed, ExxonMobil, Sorrento Therapeutics and AES
PR Newswire - Tue Dec 16, 8:30AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
SRNE: 11.41 (+0.56)
Sorrento up on news of collaboration with Abraxane inventor
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 12:40PM CST
SRNE: 11.41 (+0.56)
